FDA reconsiders COVID-19 booster approvals, with Makary emphasizing the need for “good data”
FDA reconsiders COVID-19 booster approvals, with Makary emphasizing the need for “good data” The FDA is reconsidering its approach to COVID-19 vaccine approvals for the upcoming season, citing insufficient data on booster effectiveness and declining public trust in vaccination recommendations. FDA …
Read More